Recent Updates
Recently added Catalysts

NG Shield

Phase 2

Intubation, Nasogastric | Unknown | Gastrointestinal |FEED|Last Updated: Mar 25, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment24

FDA Designations

No designations recorded

Clinical trial landscape

NG Shield · 1 trial · 1 indication

Phase 2 1
NCT00781248Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube UsageIntubation, Nasogastric
COMPLETED24 Analytics
PHASE2COMPLETED
Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage
Intubation, Nasogastric
NCT0078124824
Unlock trial analytics

Study Endpoints

Primary Endpoints

Pain/discomfort levelusing flicker scale (1-10 scale)during indwelling phase
every 30 minutes for 6 hours
safety of device usage
6 hours

Secondary Endpoints

pain/Dicomfort during insertion and removal of the nasogastric tube
at t=0h and t=6h
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeSUPPORTIVE_CARE

Treatment Arms

ArmTypeDescription
1EXPERIMENTALstarting with active NG Shield
2EXPERIMENTALStarting with inactive NG Shield

Interventions

NameTypeDescription
NG ShieldDEVICEA device to reduce pain/discomfort related to nasogastric tube usage
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Subject is in good health and able to undergoes the NG tube insertion procedure, according to the PI decision 2. Subject is able to understand and answer the pain and discomfort questionnaires 3. Subject has been fasting for at least 12h prior to the insertion phase 4. Subjec...

Countries:Israel
Unlock Eligibility Criteria

Frequently asked questions about NG Shield

What is NG Shield used for?

NG Shield is an investigational medical device intended to reduce pain and discomfort related to nasogastric tube usage. It is being studied for use in intubation and nasogastric procedures, which are common in gastrointestinal care. The device is currently in Phase 2 clinical development.

Who makes NG Shield?

NG Shield is being developed by NanoVibronix, Inc., a company traded under the ticker FEED. The device is currently in Phase 2 clinical development for reducing pain and discomfort associated with nasogastric tube usage.

What phase is NG Shield in?

NG Shield is in Phase 2 clinical development. It is an investigational device, not yet approved for commercial use. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy in reducing pain and discomfort related to nasogastric tube usage.

What clinical trials is NG Shield in?

NG Shield has one completed Phase 2 clinical trial, identified as NCT00781248. This study, titled 'Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage,' enrolled 24 participants in Israel. The trial was randomized, double-blind, and controlled.

Is NG Shield the same as any other drug?

NG Shield is a unique investigational device developed by NanoVibronix, Inc. It is not known to be the same as any other drug or device. Its specific mechanism of action is not publicly detailed, but it is being studied for its ability to reduce pain and discomfort during nasogastric tube use.